European Archives - Page 879 of 1503 - European Medical Journal

Can Asynchronous Telehealth Visits Effectively Treat Overactive Bladder?

Overactive bladder is a common condition that affects 20% of females, and substantially impairs quality of life…

Prostate Artery Embolisation for Benign Prostatic Hyperplasia

BPH is the most common non-cancerous neoplasm of ageing males,1 increasing in incidence with age. The prevalence of BPH has been estimated…

EMJ Urology 10 [Supplement 1] 2022

The use of prostate artery embolisation (PAE), a minimally invasive alternative to surgical treatment options, is explored in this review article, which offers an extensive overview of different management regimens and treatment approaches for benign prostatic hyperplasia (BPH).

Solving the Mystery of PD-1 Inhibitors

Solved the mystery of how programmed cell death protein 1 (PD-1) inhibitors work on the immune system’s natural killer (NK) cells…

Can Vitamin E Enhance Immunotherapy Responses?

VITAMIN E could boost immunotherapy responses, according to researchers at The University of Texas MD Anderson Cancer Center…

Targeting the Immune System in Rare Blood Cancer Treatment

Research has indicated that treatments for rare blood cancers should target the body’s immune system as well as the cancer itself…

CRISPR Gene-Switching Shows Promise for Sickle Cell Disease and Thalassaemia

Discovery of a small, deleted region of the genome in patients of sickle cell disease has allowed researchers to use CRISPR gene editing…

COVID-19 and the Gut

In this webinar Vincent Ho from Western Sydney University, Sydney, Australia covers the pathophysiology of how COVID-19 affects the gut,

Putting Pain to Bed

We are joined by Dr Alia Medniuk, a Consultant Anaesthetist and Clinical Lead for Acute and Inpatient Pain Management at the North Bristol NHS Trust…

IME Gastroenterology Webinar | Key Insights from ECCO 2022 - An expert roundtable discussion

Join us for a roundtable discussion to gain a deeper understanding of emerging data from ECCO 2022 and real-world evidence with biosimilars.